Key points are not available for this paper at this time.
Design
Editorial
A 1973 letter to the editor discussing the package insert and unapproved uses of propranolol.
Comments and Corrections1 November 1973PropranololWILLIAM B. ABRAMS, M.D., F.A.C.P.WILLIAM B. ABRAMS, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-79-5-752 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The principal point of the recent article by Morrelli on propranolol (Ann Intern Med 78:913-917, 1973) is that the package insert is out of date. He appears to be concerned principally with new indications recommended in the literature but not included in this document. . . . I share Dr. Morrelli's opinion that the package insert does not reflect certain uses currently "unapproved."Unfortunately, some of his statements are also a bit out of date. For example, he notes that "new drugs . . . are often introduced after only limited clinical trials. . . ." Surely...References1. COLTART D and SHAND D: Plasma propranolol levels in the quantitative assessment of β-adrenergic blockade in man. Br Med J 3:731-734, 1970 CrossrefMedlineGoogle Scholar2. COLTART D, GIBSON D, and SHAND D: Plasma propranolol levels associated with suppression of ventricular ectopic beats. Br Med J 1:490-491, 1971 CrossrefMedlineGoogle Scholar3. GIBSON D, BALCON R, and SOWTON E: Clinical use of I.C.I. 50172 as an antidysrhythmic agent in heart failure. Br Med J 3:161-163, 1968 CrossrefMedlineGoogle Scholar4. SHAND D and RANGNO R: The disposition of propranolol. Pharmacology 7:159-168, 1972 CrossrefMedlineGoogle Scholar5. ZACEST R and KOCH-WESER J: Relation of propranolol plasma level to beta blockade during oral therapy. Ibid., pp. 178-185 Google Scholar6. ADELMAN A, SHAN P, and GRAMIAK R: Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J 32:804-811, 1970 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: WILLIAM B. ABRAMS, M.D., F.A.C.P.Affiliations: Ayerst Laboratories New York, New York PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySynthesis of Condensed and Uncondensed Tetrazolo[1,5-b][1,2,4]triazines as Potential Antimicrobial AgentsD 1 November 1973Volume 79, Issue 5Page: 752-754KeywordsClinical trialsDrugs ePublished: 1 December 2008 Issue Published: 1 November 1973 PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
William B. Abrams (1973) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: